Nanostics Inc

Nanostics Inc. has developed ClarityDX Prostate, a machine-learning-enabled biomarker-based test for prostate cancer screening in men aged 40 to 70. The test stands out for its ease of integration into existing clinical workflows worldwide, providing fast and more accurate (3-4x) results at a lower cost (it does not require additional procedures or visits). As of late 2023, the test is already being sold to patients. The company has additional IP around the analysis of extracellular vesicles in blood samples to identify biomarkers across a range of cancers.